Abstract
EVIDENCE-BASED ANSWER Oral or sublingual peanut immunotherapy can achieve short-term desensitization in 60% to 80% of children and adults with peanut allergy (SOR: B, meta-analysis of small RCTs and a single RCT). In patients continuing immunotherapy for 3 years (after an initial 44 weeks of treatment), tolerance decreases significantly, but can be maintained in responders for up to 8 weeks after discontinuing immunotherapy (SOR: B, single cohort study). Currently, immunotherapy for peanut allergy is considered investigational and is not recommended for routine use (SOR: C, expert opinion).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
